rs200299299

Variant summary

Our verdict is Benign. The variant received -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_012448.4(STAT5B):​c.551-5T>C variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00274 in 1,614,160 control chromosomes in the GnomAD database, including 10 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0019 ( 0 hom., cov: 30)
Exomes 𝑓: 0.0028 ( 10 hom. )

Consequence

STAT5B
NM_012448.4 splice_region, intron

Scores

2
Splicing: ADA: 0.0003130
2

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:4

Conservation

PhyloP100: 1.14

Publications

0 publications found
Variant links:
Genes affected
STAT5B (HGNC:11367): (signal transducer and activator of transcription 5B) The protein encoded by this gene is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein mediates the signal transduction triggered by various cell ligands, such as IL2, IL4, CSF1, and different growth hormones. It has been shown to be involved in diverse biological processes, such as TCR signaling, apoptosis, adult mammary gland development, and sexual dimorphism of liver gene expression. This gene was found to fuse to retinoic acid receptor-alpha (RARA) gene in a small subset of acute promyelocytic leukemias (APLL). The dysregulation of the signaling pathways mediated by this protein may be the cause of the APLL. [provided by RefSeq, Jul 2008]
STAT5B Gene-Disease associations (from GenCC):
  • growth hormone insensitivity syndrome with immune dysregulation
    Inheritance: SD Classification: DEFINITIVE Submitted by: Illumina
  • growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • growth hormone insensitivity with immune dysregulation 1, autosomal recessive
    Inheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Orphanet, G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • growth hormone insensitivity syndrome
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -13 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.82).
BP6
Variant 17-42219847-A-G is Benign according to our data. Variant chr17-42219847-A-G is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 534583.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00186 (283/152316) while in subpopulation NFE AF = 0.00306 (208/68028). AF 95% confidence interval is 0.00272. There are 0 homozygotes in GnomAd4. There are 131 alleles in the male GnomAd4 subpopulation. Median coverage is 30. This position passed quality control check.
BS2
High Homozygotes in GnomAdExome4 at 10 AR,SD,AD gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
STAT5BNM_012448.4 linkc.551-5T>C splice_region_variant, intron_variant Intron 5 of 18 ENST00000293328.8 NP_036580.2 P51692

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
STAT5BENST00000293328.8 linkc.551-5T>C splice_region_variant, intron_variant Intron 5 of 18 1 NM_012448.4 ENSP00000293328.3 P51692

Frequencies

GnomAD3 genomes
AF:
0.00186
AC:
283
AN:
152198
Hom.:
0
Cov.:
30
show subpopulations
Gnomad AFR
AF:
0.000386
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00268
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00132
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00306
Gnomad OTH
AF:
0.00191
GnomAD2 exomes
AF:
0.00163
AC:
410
AN:
251080
AF XY:
0.00155
show subpopulations
Gnomad AFR exome
AF:
0.000740
Gnomad AMR exome
AF:
0.000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00116
Gnomad NFE exome
AF:
0.00314
Gnomad OTH exome
AF:
0.00114
GnomAD4 exome
AF:
0.00283
AC:
4139
AN:
1461844
Hom.:
10
Cov.:
32
AF XY:
0.00272
AC XY:
1978
AN XY:
727232
show subpopulations
African (AFR)
AF:
0.000717
AC:
24
AN:
33480
American (AMR)
AF:
0.000671
AC:
30
AN:
44720
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39696
South Asian (SAS)
AF:
0.0000464
AC:
4
AN:
86250
European-Finnish (FIN)
AF:
0.00189
AC:
101
AN:
53414
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.00343
AC:
3815
AN:
1111988
Other (OTH)
AF:
0.00273
AC:
165
AN:
60392
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.477
Heterozygous variant carriers
0
279
558
836
1115
1394
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
148
296
444
592
740
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00186
AC:
283
AN:
152316
Hom.:
0
Cov.:
30
AF XY:
0.00176
AC XY:
131
AN XY:
74486
show subpopulations
African (AFR)
AF:
0.000385
AC:
16
AN:
41562
American (AMR)
AF:
0.00268
AC:
41
AN:
15308
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5172
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4832
European-Finnish (FIN)
AF:
0.00132
AC:
14
AN:
10622
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00306
AC:
208
AN:
68028
Other (OTH)
AF:
0.00189
AC:
4
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.495
Heterozygous variant carriers
0
17
33
50
66
83
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00261
Hom.:
0
Bravo
AF:
0.00203
EpiCase
AF:
0.00202
EpiControl
AF:
0.00237

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:4
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Benign:3
Dec 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

STAT5B: BP4, BS2 -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Growth hormone insensitivity with immune dysregulation 1, autosomal recessive Uncertain:1Benign:1
Nov 12, 2018
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

STAT5B NM_012448.3 exon 6 c.551-5T>C: This variant has not been reported in the literature but is present in 0.3% (398/128974) of European alleles, including 3 homozygotes, in the Genome Aggregation Database (http://gnomad.broadinstitute.org/variant/17-40371865-A-G). This variant is present in ClinVar (Variation ID:534583). Evolutionary conservation and computational predictive tools for this variant are limited or unavailable. This variant is an intronic variant; splice prediction tools suggest that this variant may not affect splicing. However, further studies are needed to understand its impact. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. -

Nov 05, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Growth hormone insensitivity with immune dysregulation 1, autosomal recessive;C5436546:Growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant Uncertain:1
-
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

STAT5B NM_012448.3 exon 6 c.551-5T>C: This variant has not been reported in the literature but is present in 0.3% (398/128974) of European alleles, including 3 homozygotes, in the Genome Aggregation Database (http://gnomad.broadinstitute.org/variant/17-40371865-A-G). This variant is present in ClinVar (Variation ID:534583). Evolutionary conservation and computational predictive tools for this variant are limited or unavailable. This variant is an intronic variant; splice prediction tools suggest that this variant may not affect splicing. However, further studies are needed to understand its impact. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.82
CADD
Benign
14
DANN
Benign
0.54
PhyloP100
1.1
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
0.00031
dbscSNV1_RF
Benign
0.070
SpliceAI score (max)
0.18
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs200299299; hg19: chr17-40371865; API